D. Matthew Eby

Matthew Eby has over 20 years of leadership experience in supporting life science research and consulting for military, federal public health, and international agencies. His diverse career spans basic and applied research on environmental bioremediation, designing nanomaterials to combat antimicrobial resistance, and protecting our nation against bioterrorism. He also led federal and international agencies in modernizing public health systems and pandemic response efforts. Clients have included the Air Force, Navy, Army, Centers for Disease Control and Prevention (CDC), Food and Drug Administration, and National Institutes of Health. He  has authored more than 20 peer-reviewed publications with 1000+ citations. He also is an active supporter of local community initiatives that tackle affordable housing, food insecurity, and systemic poverty.

As vice president of the U.S. Domestic Public Health Portfolio, Eby is responsible for the growth and management of Abt’s support for the Centers for Disease Control and Prevention and the Substance Abuse and Mental Health Services Administration. He also oversees business expansion in other areas of the Department of Health and Human Services, establishes strategic partnerships, and finds innovative, cost-effective solutions after assessing clients’ complex needs.

Eby came to Abt from Booz Allen Hamilton, where he supported improving and modernizing comprehensive, interconnected systems to protect the U.S. against bioterrorism. He also supported next generation assay development and enterprise laboratory data management. He began his post-doctorate career by supporting the Air Force Research Laboratory (AFRL) in assessing bioremediation of nitrotoluenes (e.g., TNT explosives) at contaminated sites. He continued to support AFRL in designing antimicrobial biomimetic nanomaterials to combat multi-resistant infectious diseases and developed microbial and enzymatic fuel cells for clean energy.

Expertise

• Public health operational excellence
• Enterprise system change management and modernization
• Laboratory IT operations and quality assurance
• Differentiated life sciences
• Complex system design and implementation

Key Projects

• Modernized disparate laboratory and quality data management systems into integrated enterprise platforms for CDC
• Provided subject matter expertise to U.S. and international agencies on next generation sequencing assay development and modernization to cloud-based platforms
• Led contract teams to support CDC’s initiative for achieving gold standards in quality assurance, including Clinical Laboratory Improvement Amendments and College of American Pathologists accreditation of infectious disease laboratories and the CDC Biorepository

Publications

• Purification and Characterization of Multicopper Oxidases for Enzyme Electrodes. 2014. DM Eby, GR Johnson. Enzymatic Fuel Cells, 123-145
• Bacterial sunscreen: layer-by-layer deposition of UV-absorbing polymers on whole-cell biosensors. 2012. DM Eby, S Harbaugh, RN Tatum, KE Farrington, N Kelley-Loughnane, et al. Langmuir 28 (28), 10521-10527
• Hybrid antimicrobial enzyme and silver nanoparticle coatings for medical instruments. 2009. DM Eby, HR Luckarift, GR Johnson. ACS applied materials & interfaces 1 (7), 1553-1560
• Lysozyme catalyzes the formation of antimicrobial silver nanoparticles. 2009. DM Eby, NM Schaeublin, KE Farrington, SM Hussain, GR Johnson. ACS nano 3 (4), 984-994